Table 3 Baseline characteristics of the identified subgroup of ACPA-negative RA compared to the remaining ACPA-negative RA patients
SDFR and DAS4 months < 1.6 | SDFR and DAS4 months ≥ 1.6 | No SDFR and DAS4 months > 1.6 | No SDFR and DAS4 months ≥ 1.6 | |
|---|---|---|---|---|
Age (years), mean (SD) | 64 (12) | 64 (11) | 60 (14) | 59 (14) |
Gender (female), % | 55 | 21 | 33 | 50 |
Sympt. duration (≤ 12 weeks), % | 64 | 38 | 33 | 56 |
RF-positive, % | 27 | 21 | 45 | 50 |
DAS44 at baseline, median (IQR) | 3.2 (2.5–4.1) | 3.6 (3.1–4.5) | 3.4 (3.0–4.1) | 2.8 (2.4–3.8) |
HAQ-DI at baseline, median (IQR) | 1.0 (0.6–1.6) | 1.3 (0.8–1.6) | 1.3 (0.9–1.5) | 0.7 (0.3–1.2) |
SJC (0–44) at baseline, median (IQR) | 8 (3–13) | 7 (3–11) | 8 (2–11) | 5 (2–11) |
TJC (0–53) at baseline, median (IQR) | 5 (3–10) | 9 (6–19) | 11 (6–19) | 7 (3–11) |
ESR at baseline, median (IQR) | 29 (22–38) | 34 (6–60) | 22 (11–36) | 18 (10–41) |
VAS at baseline (0–100), median (IQR) | 60 (30–80) | 60 (40–80) | 40 (30–60) | 45 (20–55) |
CRP at baseline (μg/ml), median (IQR) | 18.0 (8.7–26.3) | 11.0 (3.0–22.7) | 7.0 (3.0–28.5) | 9.3 (5.0–46.9) |